Disc medicine presents positive clinical and translational data across portfolio at the 66th american society of hematology (ash) annual meeting

Watertown, mass., dec. 09, 2024 (globe newswire) -- disc medicine, inc. (nasdaq:iron), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today spotlights 8 posters presented at the ash 2024 annual meeting in san diego, ca. this year's presentations included updates from the beacon and aurora trials of bitopertin in patients with erythropoietic protoporphyria (epp) and the phase 1 sad/mad trial of disc-3405 in healthy volunteers. additionally, disc presented a real-world patient survey highlighting the disease burden of epp and multiple preclinical models highlighting the potential benefits of bitopertin, disc-0974, and disc-3405 in existing and new indications. the collection of data supports disc's continued advancement of all three clinical candidates and provides evidence for expansion opportunities in new indications.
ASH Ratings Summary
ASH Quant Ranking